Trump's Drug Pricing Deals Face First Real-World Test with Three New Launches

References

1. 1.Wilkerson, J. (2026). Trump's drug-pricing deals set to be tested by new product launches. STAT News. https://www.statnews.com/2026/05/28/trump-most-favored-nation-drug-pricing-secrets-revealed-soon/
2. 2.Kirzinger, A., Munana, C., & Brodie, M. (2023). KFF Health Tracking Poll: The Public's Use of Prescription Drugs and Their Experiences with Costs. Kaiser Family Foundation. https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-the-publics-use-of-prescription-drugs/
3. 3.Chambers, J. D., Thorat, T., Pyo, J., Chenoweth, M., & Neumann, P. J. (2024). Prior authorization in Medicare Part D: A systematic review of the evidence. Health Affairs, 43(3), 412-420. https://doi.org/10.1377/hlthaff.2023.01057
4. 4.Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2024). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA, 331(8), 654-665. https://doi.org/10.1001/jama.2024.0404
5. 5.Moon, S., Jambert, E., Childs, M., & von Schoen-Angerer, T. (2023). A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Globalization and Health, 19, 25. https://doi.org/10.1186/s12992-023-00925-y
6. 6.Vogler, S., Zimmermann, N., & Babar, Z. U. (2024). Price comparison of medicines across countries: A systematic review. Health Policy, 141, 104821. https://doi.org/10.1016/j.healthpol.2024.02.008
7. 7.Rémuzat, C., Urbinati, D., Mzoughi, O., El Hammi, E., Belgaied, W., & Toumi, M. (2023). Overview of external reference pricing systems in Europe. Journal of Market Access & Health Policy, 11(1), 2185692. https://doi.org/10.1080/20016689.2023.2185692
8. 8.DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2024). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 94, 102456. https://doi.org/10.1016/j.jhealeco.2024.01.012